<DOC>
	<DOC>NCT00995930</DOC>
	<brief_summary>This study will evaluate the effect of ACZ885 on vascular function in patients with documented atherosclerotic disease and T2DM or IGT.</brief_summary>
	<brief_title>Safety &amp; Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<criteria>Patients with known atherosclerotic disease and documented diagnosis of T2DM for ≤ 14 years OR IGT HbA1c between 6.0% and 10.0% On stable statin therapy or statin intolerant Patients who are eligible and able to participate in the study Contraindications to MRI NYHA class IV Heart Failure NYHA class I III heart failure with acute exacerbation in 3 months prior to screening Patients with type 1 diabetes Acute infections HsCRP &gt; 30 mg/dL Aortic aneurysm ≥5cm Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Atherosclerosis,</keyword>
	<keyword>Type 2 Diabetes Mellitus, T2DM,</keyword>
	<keyword>Cardiovascular Diseases, ACZ885, impaired glucose tolerance, IGT, Canakinumab</keyword>
</DOC>